Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, G.J. Veldhuis, Rogier Mous, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Johan A. Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Carsten Utoft Niemann